Rational polypharmacological targeting of FLT3, JAK2, ABL, and ERK1 suppresses the adaptive resistance to FLT3 inhibitors in AML.
Blood Advances
Azhar, Mohammad M; Kincaid, Zachary Z; Kesarwani, Meenu M; Menke, Jacob J; Sweiterman, Joshua J; Ansari, Sekhu S; Reaves, Angela A; Ahmed, Arhama A; Shahzad, Rammsha R; Khan, Areeba A; Syed, Nuha N; Amir, Noor N; Wunderlich, Mark M; Latif, Tahir T; Seibel, William L WL; Azam, Mohammad M
Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia.
Npj Precision Oncology
Downes, Charlotte E J CEJ; McClure, Barbara J BJ; Bruning, John B JB; Page, Elyse E; Breen, James J; Rehn, Jacqueline J; Yeung, David T DT; White, Deborah L DL
Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance.
Scientific Reports
Kesarwani, Meenu M; Huber, Erika E; Kincaid, Zachary Z; Evelyn, Chris R CR; Biesiada, Jacek J; Rance, Mark M; Thapa, Mahendra B MB; Shah, Neil P NP; Meller, Jarek J; Zheng, Yi Y; Azam, Mohammad M